TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Neurocognitive Effects of Gluten Exposure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. 18-50 years of age~3. Celiac Disease Group: Positive small intestinal biopsies meeting Marsh II or III histologic criteria for celiac disease at least six months since the time of study entrance as well as positive IgA anti-tissue transglutaminase antibody or positive IgA/IgG anti-Deamidated Gliadin Peptide (DGP) with normal serum IgA~4. Non-Celiac Gluten Sensitive Group: Negative small intestinal biopsies and negative IgA anti-tissue transglutaminase (tTG) or negative IgA/IgG anti-Deamidated Gliadin Peptide (DGP) with normal serum IgA, but with symptomatic response to gluten withdrawal~5. Subject should have well controlled celiac disease and have been on a gluten-free diet for at least six months prior to study enrollment~6. Subject must provide informed consent, as approved by the Institutional Review Board, and agree to complete required study visits, blood work neuropsychological testing and a urine pregnancy test (if applicable).~7. Subject agrees to use appropriate birth control for the duration of the study.~Exclusion Criteria:~1. Subject has other food intolerances or food allergies (other than gluten) that would interfere with the conduct of the study (e.g. corn starch, soy).~2. Subject has a history of severe, acute symptomatic reactions to sporadic gluten ingestion~3. Subject has any chronic active gastrointestinal disease other than celiac disease (e.g. Crohn's disease, irritable bowel syndrome, autoimmune enteropathy, eosinophilic enteritis).~4. Subject should not have daily symptoms concerning for brain fog such as mental confusion or difficulty concentrating, at baseline.~5. Subject has symptomatic neurological or psychiatric disease(s) that would interfere with the conduct of the study.~6. Subject should not have been on corticosteroids or other immunosuppressive agents in the past 3 months.~7. Significant other co-morbidity as determined by the Principal Investigator~8. Subject is deemed inappropriate by the Principal Investigator.~9. Subject is pregnant or breast-feeding at time of participation.~10. Subject weighs less than 110 pounds.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Crossover Group 1 (Type: EXPERIMENTAL): Group 1 will consume 4 grams of gluten before neurocognitive testing at Visit 2.~Group 1 will consume placebo before neurocognitive testing at Visit 3.
- Crossover Group 2 (Type: EXPERIMENTAL): Group 2 will consume placebo before neurocognitive testing at Visit 2.~Group 2 will consume 4 grams of gluten before neurocognitive testing at Visit 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically Confirmed Non Small Cell Lung Cancer.~* Locally advanced disease previously treated with combined therapy (chemotherapy and surgery with or without radiotherapy, or chemotherapy and radiotherapy).~* Chemotherapy with regimens containing cisplatin or carboplatin is mandatory~* Response to combined therapy~Exclusion Criteria:~* No previous treatment with ZD1839 or any other EGFR-targeted therapy~* No progressive disease after combined therapy for locally advanced NSCLC~* No presence of metastatic disease~* No other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ~* Any unresolved chronic toxicity from previous anticancer therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and non-pregnant, non-lactating females age ≥ 18 years.~* Provide written, informed consent.~* Prior completion of an avoralstat therapeutic study OR a confirmed diagnosis of HAE Type 1 or HAE Type 2.~* Access to appropriate medication for the treatment of acute HAE attacks.~* Adequate contraception.~Exclusion Criteria:~* Females who are pregnant or breast feeding.~* Clinically significant medical condition or medical history.~* Abnormal screening ECG, laboratory or urinalysis finding that is clinically significant.~* Investigational drug exposure within 30 days (except avoralstat).~* History of or current alcohol or drug abuse.~* HIV or active HBV or HCV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- avoralstat (Type: EXPERIMENTAL): Five avoralstat capsules (100 mg) to be taken three times daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Patients with Ulcerative Colitis (UC) who were previously randomized and have completed the 8-week treatment in ACT12688 study with an acceptable safety profile. Patients who for administrative reasons could not be enrolled in the LTS12593 study right after completion of the 8-week treatment in the ACT12688 study must be enrolled within 3 months from the end of the ACT12688 study~* Signed written informed consent for Study LTS12593~Exclusion criteria:~* Patient with any adverse event leading to study drug (active or placebo) treatment discontinuation from ACT12688 study.~* Patient with any abnormalities or adverse events that per investigator judgment would adversely affect patient's participation in the long-term extension study.~* Use of any immunosuppressant (if patient is on immunosuppressant he or she must discontinue immunosuppressant before starting the LTS12593).~* If the patient started biological treatment for UC while waiting to be enrolled in the LTS12593, then he or she must stop the biological treatment and must have 8 weeks of wash out period before starting treatment with SAR339658 (only anti-tumor necrosis factors (TNFs) are allowed)~* Patients exposed to an anti-integrin or any investigational drug administered after the end of treatment in ACT12688~* Positive pregnancy test~* Breast feeding woman~* Women of childbearing potential not protected by highly effective contraceptive method of birth control and/or who are unwilling and unable to be tested for pregnancy.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SAR339658 (Type: EXPERIMENTAL): SAR339658, every 2 weeks (Q2W) or every 4 weeks (Q4W) according to clinical response at Week 8 in the ACT12688 trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Immunoregulatory Dysfunction in Trauma Patients: Role of Obesity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. age 18 and older~2. traumatic injury of sufficient severity that ICU care is anticipated~3. Likely (by clinical criteria) to survive for at least 7 days after enrollment~Exclusion Criteria:~1. age less than 18 (not at risk for ARDS)~2. minor trauma not requiring ICU monitoring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * Organ-confined disease~ * cT1, cT2, or cT3 tumors~    * Patients with cT1 tumors are eligible if ≥ 1 core biopsies have ≥ 50% of the tumor OR if 50% of the cores examined contain the tumor~ * No small cell carcinoma of the prostate~* Scheduled for radical prostatectomy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Not specified~Life expectancy~* Not specified~Hematopoietic~* Platelet count ≥ 100,000/mm\^3~* WBC ≥ 3,500/mm\^3~Hepatic~* ALT and AST ≤ 4 times normal~* Bilirubin ≤ 2 mg/dL~Renal~* Creatinine ≤ 2 times upper limit of normal~* Calcium ≤ 10.5 mg/dL~* No detectable renal stones by CT scan or ultrasound~Other~* No history of diabetes mellitus requiring pharmacotherapy~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* More than 5 years since prior antiestrogens, antiandrogens, luteinizing hormone-releasing hormone agonists, estrogen, or progestational agents~Radiotherapy~* Not specified~Surgery~* See Disease Characteristics~* No prior nephrectomy~* No prior prostatic surgery~* No prior cryotherapy or transurethral resection of the prostate

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Stage 1, Arm I (Type: EXPERIMENTAL): Patients receive oral dexamethasone once daily on days 1-4 and oral calcitriol once daily on days 2-4 weekly for 4 weeks before surgery.
- Stage 1, Arm II (Type: EXPERIMENTAL): No study drugs before surgery.
- Stage 1 Arm 3 (Type: EXPERIMENTAL): Patients receive oral dexamethasone once daily on days 1-4.
- Stage 1, Arm 4 (Type: EXPERIMENTAL): Patients receive oral calcitriol once daily on days 2-4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Natural Antioxidant Supplement on Sperm DNA Fragmentation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-Sperm Chromatin \>16%, sufficient ejaculate sperm for ICSI~Exclusion Criteria:~* Severe male factor infertility

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: None

Study Arms:
- Treatment group (Type: None): Male patients exposed to antioxidant for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Rectal Dialysis Technique to Measure Rectal 5-ASA Levels in Healthy Volunteers Receiving Asacol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible subjects would be healthy males and females~* 18-45 years of age (inclusive)~* Within 20% of normal body weight at screening~* Who are able to give written informed consent.~Exclusion Criteria:~* History of any chronic illness~* Evidence of significant organic or psychiatric disease on a brief health questionnaire~* A history or presence of any condition causing malabsorption or an effect on gastrointestinal motility~* A history of any gastrointestinal surgery~* A history of acute or chronic renal insufficiency~* Pre existing liver disease~* A history of severe allergic reaction to salicylates, aminosalicylates or any of the ingredients of Asacol® tablets or a history of multiple food/drug allergies or if they are pregnant or lactating.~* Subjects will be required to refrain from any prescription or nonprescription drug or herbal products except their birth control medications for gastrointestinal disorders for 7 days prior to dosing and during the study, till its completion at the end of the fifth visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1200 mg Asacol once daily for 1 week (Type: ACTIVE_COMPARATOR): Rectal dialysis will be done after 1 week on 1200 mg asacol
- 2400 mg Asacol once daily for 1 week (Type: ACTIVE_COMPARATOR): Rectal dialysis will be done after 1 week on 2400 mg asacol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Vepoloxamer in Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 through 74~* Duration of documented heart failure \>3 months~* On stable concomitant medication regimen ≥4 weeks~* Left ventricular ejection fraction ≤35%~* Systolic blood pressure ≥90 mmHg~Exclusion Criteria:~* Severe valvular stenosis or primary valvular regurgitation as the cause of heart failure~* History of myocardial infarction, coronary artery bypass graft surgery, or percutaneous intervention within the prior 3 months~* Estimated glomerular filtration rate ≤45 mL/min/1.73 m2~* Acutely decompensated heart failure within 1 month prior to the screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vepoloxamer - Low dose (Type: EXPERIMENTAL): Vepoloxamer injection administered intravenously 225 mg/kg over 3 hours
- Vepoloxamer - High dose (Type: EXPERIMENTAL): Vepoloxamer injection administered intravenously 450 mg/kg over 3 hours
- 5% dextrose in water (D5W) (Type: PLACEBO_COMPARATOR): D5W administered intravenously over 3 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of rectal cancer or neoplastic polyp (i.e. intramucosal carcinoma, carcinoma in situ)~* BFI score must meet at least one of the below criteria:~  * Total BFI \< 50~ * Dietary subscale \< 11~ * Frequency subscale \< 19~ * Urgency subscale \< 12~* English speaking~* Patients ≥18 years old. age~* Sphincter-preserving surgery and ≥ 12 months after restoration of bowel continuity~Exclusion Criteria:~* Locally recurrent or metastatic disease~* Immune suppressive medication~* Seizure disorder~* Prior sacral/lower spinal surgery~* Congenital Spinal defect/Paraplegia~* Rectal prolapse~* IBD/Crohn's~* Pregnancy~* Active anal/rectal abscess~* Pacemaker or other electronic implanted device~* Immediate need for MRI~* At the time of the wire stimulation procedure, patients will be excluded if the surgeon is unable to place the temporary stimulating lead~* Inability to commit to local follow up for device management.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- InterStimTM the device on (Type: EXPERIMENTAL): The device will be set to stimulate for 4 weeks, then off for two weeks, and then the device will be on but will not stimulate for 4 weeks.
- InterStimTM the device off (Type: EXPERIMENTAL): The device will be on but will not stimulate for 4 weeks, then off for two weeks, and then the device will be set to stimulate for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Rhinitis With Intranasal Vitamin E

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical symptoms of rhinitis and symptom severity score of 25 or higher on the self-administered Rhinosinusitis Questionnaire (range of 0, i.e. absence of any symptom, to 50, which indicates the most severe symptom in each category)~Exclusion Criteria:~* Inability to give informed consent, comprehend questions or instructions and complete questionnaires~* Recent change (within 2 weeks) in the medications that may affect nasal or sinus symptoms (intranasal or systemic glucocorticosteroids, mast cell stabilizer, antihistamines, decongestants, leukotriene antagonist, antibiotics, preparations containing thyroid or sex hormones, alpha-blocking agents)~* Intranasal use of oil- or gel-based products

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven diagnosis of unresectable B3 thymoma or thymic carcinoma recurrent or progressing after prior chemotherapy (only one prior systemic therapy allowed)~* Presence of measurable disease~* Age \>=18 years~* ECOG performance status 0-1~* Negative pregnancy test (if female in reproductive years)~* Use of effective contraceptive methods if men and women of child producing potential~* Adequate liver function Total Serum Bilirubin \<=1.5 x upper limit of normal (ULN) Transaminases (AST/ALT) \<=2.5ULN (if liver metastases are present, then \<=5ULN is allowed) ALP \<=2.5ULN (if liver and/or bone metastases are present, then \<=5ULN is allowed)~* Adequate renal function Serum Creatinine \<=ULN or Creatinine Clearance calculated by Cockcroft and Gault's formula \> 60 mL/min.~* Adequate hematologic status ANC \>=1,500cells/mm3 Platelet Count \>=100,000cells/mm3 Hemoglobin \>=9.0g/dL~* Two weeks must have elapsed since completion of prior chemotherapy, minor surgery, radiotherapy (provided that no more than 25% of bone marrow reserve has been irradiated)~* Resolution of all acute toxic effects of any prior treatments to NCI CTC (Version 3.0) grade \<=1~Exclusion Criteria:~* Any of the following in the past 6 months: myocardial infarction, uncontrolled cardiac arrhythmia, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis~* Grade \>1 retinopathy~* Known brain metastases~* Known active infections~* Pregnant or breast feeding women~* Diabetes mellitus uncontrolled~* Gastrointestinal disease that would impact on drug absorption~* Patients under treatment with anticoagulants or with coagulation disorders or with signs of hemorrhage at baseline~* Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that make the patient inappropriate for entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Milciclib Maleate (PHA-848125AC) (Type: EXPERIMENTAL): 100 and 50 mg Capsule 150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Indication for IVF / ICSI - treatment~* Age ≥ 18 years and ≤ 35 years~* Ovarian reserve parameters in the adequate age - range, determined by Anti-Mullerian-Hormone (AMH) and Antral Follicle Count (AFC)(16)~* Able to understand the aim of the study and to provide consent~* Regular cycle (25-35 days)~Exclusion Criteria:~* Diagnosis of polycystic ovarian syndrome (PCOS) Rotterdam criteria~* Endometriosis stage 3 or 4 AFS~* Treatment with GnRH-analogues during the previous 6 months~* Intake of oral contraceptive pill (OCP) or any hormonal treatment during the last 3 months

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues